Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5764227 in previously treated advanced gastrointestinal solid tumors
2025-520672-26-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan in gastrointestinal neoplasia, colorectal adenocarcinoma and pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by GSK. Primary endpoint: Confirmed objective response rate (ORR). Planned start Sep 2025; status: authorised.
02
Drugs
risvutatug rezetecan
03
Conditions
gastrointestinal neoplasiacolorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-520672-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520672-26-00.